The effects of inpatient hybrid closed-loop therapy initiated within 1 week of type 1 diabetes diagnosis.

ABSTRACT:

Background

This article describes our experience with inpatient hybrid closed-loop control (HCLC) initiated shortly after the diagnosis of type 1 diabetes in a randomized trial designed to assess the effectiveness of inpatient HCLC followed by outpatient sensor-augmented pump (SAP) therapy on the preservation of β-cell function.

Subjects and methods

Forty-eight individuals with newly diagnosed type 1 diabetes and positive pancreatic autoantibodies (7.8-37.7 years old) received inpatient HCLC therapy for up to 93 h, initiated within 7 days of diagnosis.

Results

On initiation of HCLC, mean glucose concentration was 240±100 mg/dL. During the first day of HCLC, median of the participant's mean glucose concentrations fell rapidly to 146 mg/dL, a level of control that was s

SUBMITTER: Diabetes Research in Children Network (DirecNet) Study Group 

PROVIDER: S-EPMC3643224 | biostudies-literature | 2013 May

REPOSITORIES: biostudies-literature